Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of FCF Margin data on file, last reported at 26.07% in Q1 2026.

• Quarterly FCF Margin rose 491.0% year-over-year to 26.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.66% (up 250.0% YoY) and the FY2025 annual result came in at 22.51%, up 543.0% from the prior year.
• FCF Margin grew to 26.07% in Q1 2026, from 6.74% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 41.21% in Q3 2025 to a low of 23.5% in Q4 2022.
• A 5-year average of 12.77% and a median of 14.93% in 2023 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin slumped 3240 bps — and 2023, when it surged 3342 bps.
• Tracing BMRN's FCF Margin over 5 years: stood at 23.5% in 2022, then soared by 142 bps to 9.92% in 2023, then surged by 124 bps to 22.23% in 2024, then plunged by 70 bps to 6.74% in 2025, then surged by 287 bps to 26.07% in 2026.
• The last three FCF Margin figures came in at 26.07% (Q1 2026), 6.74% (Q4 2025), and 41.21% (Q3 2025), per Business Quant data.